See more : Fair Isaac Corporation (0TIQ.L) Income Statement Analysis – Financial Results
Complete financial analysis of Celcuity Inc. (CELC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Celcuity Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Watahan & Co.,Ltd. (3199.T) Income Statement Analysis – Financial Results
- RELX PLC (REN.AS) Income Statement Analysis – Financial Results
- Allied Cooperative Insurance Group (8150.SR) Income Statement Analysis – Financial Results
- Canadian Utilities Limited (CDUUF) Income Statement Analysis – Financial Results
- Innospec Inc. (IOSP) Income Statement Analysis – Financial Results
Celcuity Inc. (CELC)
About Celcuity Inc.
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 142.77K | 210.92K | 303.24K | 385.59K | 339.00K | 223.04K | 104.70K | 73.06K | 58.38K |
| Gross Profit | -142.77K | -210.92K | -303.24K | -385.59K | -339.00K | -223.04K | -104.70K | -73.06K | -58.38K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 60.59M | 35.29M | 25.76M | 7.68M | 6.27M | 6.33M | 4.98M | 3.06M | 2.01M |
| General & Administrative | 5.64M | 4.10M | 2.60M | 1.87M | 1.54M | 1.61M | 972.52K | 263.66K | 250.09K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.64M | 4.10M | 2.60M | 1.87M | 1.54M | 1.61M | 972.52K | 263.66K | 250.09K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 66.23M | 39.39M | 28.36M | 9.56M | 7.81M | 7.93M | 5.95M | 3.33M | 2.26M |
| Cost & Expenses | 66.23M | 39.39M | 28.36M | 9.56M | 7.81M | 7.93M | 5.95M | 3.33M | 2.26M |
| Interest Income | 2.45M | 1.13M | 13.26K | 82.11K | 446.10K | 448.83K | 152.88K | 18.02K | 268.00 |
| Interest Expense | 0.00 | 2.11M | 1.26M | 120.00 | 159.00 | 111.00 | 451.66K | 0.00 | 0.00 |
| Depreciation & Amortization | 142.77K | 210.92K | 303.24K | 385.59K | 339.00K | 223.04K | 104.70K | 73.06K | 58.38K |
| EBITDA | -58.31M | -39.18M | -28.05M | -9.17M | -7.47M | -7.71M | -5.85M | -3.26M | -2.20M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -66.23M | -39.39M | -28.36M | -9.56M | -7.81M | -7.93M | -5.95M | -3.33M | -2.26M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 2.45M | -978.95K | -1.25M | 81.99K | 445.94K | 451.72K | -298.79K | 18.02K | 268.00 |
| Income Before Tax | -63.78M | -40.37M | -29.61M | -9.47M | -7.36M | -7.48M | -6.25M | -3.31M | -2.26M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 978.95K | 959.12K | -385.47K | -338.84K | 451.83K | 48.18K | 0.00 | 0.00 |
| Net Income | -63.78M | -41.35M | -30.56M | -9.09M | -7.02M | -7.48M | -6.25M | -3.31M | -2.26M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.69 | -2.68 | -2.28 | -0.89 | -0.69 | -0.74 | -0.84 | -0.49 | -0.36 |
| EPS Diluted | -2.69 | -2.68 | -2.28 | -0.89 | -0.69 | -0.74 | -0.84 | -0.49 | -0.36 |
| Weighted Avg Shares Out | 23.68M | 15.42M | 13.38M | 10.27M | 10.23M | 10.12M | 7.46M | 6.72M | 6.31M |
| Weighted Avg Shares Out (Dil) | 23.68M | 15.42M | 13.38M | 10.27M | 10.23M | 10.12M | 7.46M | 6.72M | 6.31M |
Celcuity to Participate in 22nd Annual Needham Virtual Healthcare Conference
MINNEAPOLIS, MN / ACCESSWIRE / April 12, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced its participation in the 22nd Annual Needham Virtual Healthcare Conference. Brian Sullivan, Chairman, Chief...
Celcuity Inc. (CELC) Q4 2022 Earnings Call Transcript
Celcuity Inc. (NASDAQ:CELC ) Q4 2022 Earnings Conference Call March 23, 2023 4:30 PM ET Company Participants Robert Uhl - ICR Westwicke, IR Brian Sullivan - CEO and Co-Founder Vicky Hahne - CFO Igor Gorbatchevsky - Chief Medical Officer Conference...
Celcuity Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Dosing of first patient in VIKTORIA-1 in the fourth quarter triggered closing of $100 million PIPE financing and drawdown of $20 million term loan tranche, which extends cash runway through 2025 Updated clinical data from the Phase 1b advanced breast...
Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2022 Financial Results and Webcast/Conference Call
MINNEAPOLIS, MN / ACCESSWIRE / March 16, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced that it will release its financial results for the fourth quarter and full year...
Celcuity to Present Preclinical Data on Therapeutic Effects of Gedatolisib in Gynecological Cancer Models at AACR Annual Meeting 2023
MINNEAPOLIS, MN / ACCESSWIRE / March 15, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced publication of an abstract reporting data from preclinical studies evaluating gedatolisib and other PI3K/AKT/mTOR...
Celcuity to Participate in Cowen's 43rd Annual Health Care Conference
MINNEAPOLIS, MN / ACCESSWIRE / March 1, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced its participation in Cowen's 43rd Annual Health Care Conference to be held in Boston...
Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Prostate Cancer at ASCO GU Cancers Symposium
Gedatolisib demonstrated superior potency and efficacy in prostate cancer cell lines compared to other PI3K/AKT/mTOR inhibitors evaluated regardless of PI3K or PTEN status MINNEAPOLIS, MN / ACCESSWIRE / February 16, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused...
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Celcuity Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
NEW YORK , Dec. 20, 2022 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Celcuity Inc. (NASDAQ:...
Celcuity Closes $100 Million Private Placement
MINNEAPOLIS, MN / ACCESSWIRE / December 12, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company, today announced the closing of its private placement, resulting in gross proceeds of approximately $100 million, before deducting placement agent fees and other expenses....
Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Patients with Advanced Breast Cancer at the 2022 San Antonio Breast Cancer Symposium
High response rates and encouraging median progression free survival rates were observed in patients regardless of PIK3CA mutation status Median progression free survival (PFS) of 42.3 months was reported for patients who were treatment naïve in the advanced setting MINNEAPOLIS,...
Source: https://incomestatements.info
Category: Stock Reports